Valuation: Beijing Bohui Innovation Biotechnology Group Co., Ltd.

Market Cap 4.33B 648M 579M 538M 490M 925M 62.67B 928M 6.49B 2.54B 31.99B 2.43B 2.38B 103B P/E 2024
506x
P/E 2025 -55.7x
Enterprise Value 5.33B 798M 714M 663M 604M 1.14B 77.19B 1.14B 7.99B 3.12B 39.4B 3B 2.93B 126B EV / Sales 2024
6.63x
EV / Sales 2025 7.43x
Free-Float
37.78%
Yield 2024 *
-
Yield 2025 -
08-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Announces Changes to Its Board CI
04-27 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-23 Beijing Bohui Innovation Biotechnology Group Co., Ltd. announced that it expects to receive CNY 300 million in funding CI
01-14 Bohui Innovation Biotechnology Gets Clinical Trial Approval for Anti-Rabies Human Rabies MT
11-12 Bohui Innovation Biotechnology JV Gets Clinical Trial Approval for Hib Vaccine MT
25-10-29 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-27 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-06-02 Bohui Innovation Biotechnology Secures Approval for Virus Detection Kit MT
25-04-28 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-21 Beijing Bohui Innovation Biotechnology Group Subsidiary Gains Clinical Trial Approval for Flu Vaccine MT
1 day+2.51%
1 week+1.34%
Current month+1.34%
1 month+2.71%
3 months+20.18%
6 months-10.47%
Current year-15.47%
1 week 5.07
Extreme 5.07
5.32
1 month 4.71
Extreme 4.71
5.32
Current year 4.06
Extreme 4.06
8.17
1 year 4.06
Extreme 4.06
8.63
3 years 3.43
Extreme 3.43
8.63
5 years 3.43
Extreme 3.43
12.28
10 years 3.43
Extreme 3.43
23.8
Manager TitleAgeSince
Chief Executive Officer 56 2020-03-16
Director of Finance/CFO 42 2020-06-28
Corporate Officer/Principal 48 2020-03-16
Director TitleAgeSince
Chairman 58 2014-05-18
Director/Board Member 59 2020-06-28
Chairman 48 2022-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
11/2/21 Sell

Executive/Senior Manager

268,300 0.0364%
9/15/21 Sell

Executive/Senior Manager

50,000 0.0068%
1/26/21 Buy

Chairman

29,000 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+2.51%+1.34%-4.68%-6.36% 646M
+0.83%+3.19%+37.87%+106.25% 1,051B
+1.93%+2.11%+36.82%+64.90% 630B
+1.49%+5.19%+19.84%+85.41% 489B
+2.26%+0.90%+66.40%+39.33% 359B
+1.45%+3.50%+21.87%+42.64% 344B
+1.17%+2.37%+11.71%+35.14% 272B
+0.89%+1.08%-7.28%+10.52% 246B
+1.82%+2.94%+40.43%+52.78% 224B
+2.77%+4.44%+29.49%+101.40% 187B
Average +1.71%+2.53%+25.25%+53.20% 380.44B
Weighted average by Cap. +1.47%+2.44%+31.56%+69.95%

Financials

2024 2025
Net sales 852M 127M 114M 106M 96.43M 182M 12.33B 183M 1.28B 499M 6.29B 479M 468M 20.17B 825M 123M 110M 103M 93.36M 176M 11.93B 177M 1.24B 483M 6.09B 463M 453M 19.53B
Net income 9.25M 1.38M 1.24M 1.15M 1.05M 1.98M 134M 1.98M 13.85M 5.42M 68.32M 5.2M 5.08M 219M -91.92M -13.75M -12.3M -11.43M -10.41M -19.64M -1.33B -19.7M -138M -53.86M -679M -51.65M -50.52M -2.18B
Net Debt 974M 146M 130M 121M 110M 208M 14.1B 209M 1.46B 571M 7.2B 547M 535M 23.06B 1B 150M 134M 125M 114M 214M 14.52B 215M 1.5B 588M 7.41B 564M 551M 23.76B
Projected Income Statement - Annual - Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Logo Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Beijing Bohui Innovation Biotechnology Group Co Ltd, formerly Beijing Bohui Innovation Biotechnology Co Ltd is a China-based company mainly engaged in testing and biological products. The testing business products are divided into testing instruments and testing reagents, including human papillomavirus (HPV) testing products, trace element testing products, mass spectrometry related testing products, and others. The biological products mainly cover three categories: albumin, immunoglobulin and human coagulation factors, including human serum albumin, human immunoglobulin, intravenous human immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, and others. The Company mainly operates its business in the domestic market.
Employees
2,170
Date Price Change Volume
26-10-09 CN¥5.300 +2.51% 10,679,501
  1. Stock Market
  2. Stocks
  3. 300318 Stock